anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Suitable candidates who meet the inclusion criteria will be approached to participate.

Patients hospitalized with a diagnosis of acute radicular pain or pain due to renal colic in the emergency department of the Hadassah Medical Center - Ein Kerem Hebrew University. The indications for performing the treatment are: strong (sharp) pain that lasts for several days and radiates from the back to the leg (ie radicular pain) or pain due to a renal colic. Patients that are suffering from severe enough pain that drives them to the emergency room. The study focuses on patients suffering from radiating nerve pain on the background of acute dyskopia = pain resulting from pressure and inflammation on a nerve root causing sciatic pain and also on patients suffering from renal colic.

This study aims to evaluate the efficacy of cannabis for the treatment of radicular pain and renal colic pain.

These patients will usually also be treated with opiate-type painkillers due to the intense pain. We will test whether there is pain relief and a reduction in the need to use opiates. After oral and written informed consent has been obtained, all patients will be admitted for observational treatment as is customary for a pain patient connected to a PCA pump for 24 hours. After Administering an initial loading dose of morphine 0.05-0.1 mg/kg intravenously, as is customary in a pain patient, the patient will be connected to an accepted protocol of morphine infusion for pain relief under the patient's control as follows: 1 mg upon request, 10 minutes downtime, no background , a maximum hourly dose of 6 mg. The patients will be randomly assigned to one of the following dose groups: 1. High dose of cannabis oil: drops of oil to administer under the tongue (21.6 mg THC, 20 mg CBD). 2. High dose of cannabis oil in split form: half a dose at time t0, half a dose an hour later. b oil drops to administer under the tongue (21.6 mg THC, 20 mg CBD). 3. Low dose of cannabis oil: oil drops to administer under the tongue (10.8 mg THC, 10 mg CBD. 4. Placebo control: A control group will receive olive oil, which is similar in taste and appearance to cannabis oil. The treatments will be given so that the subjects, the researchers-therapists and the results analysts will remain blinded until the end of the recruitment. Blinding of the research drug will be obtained by using similar bottles of the cannabis or placebo-olive oil which will be given in a similar container coated with the same cover and with the same taste. In order to maintain blinding even in the split dose, all other groups will receive the placebo after one hour. It should be noted that participants in the study will continue to receive the standard treatment currently given to patients in the same condition
iGlucose Remote Monitoring System. iGlucose is a remote patient monitoring system. The iGlucose monitor works by analyzing a small amount of blood placed on a strip that is inserted into the monitor, similar to a standard glucometer. The iGlucose monitor will show the patient their glucose reading and will automatically send the patient's glucose reading to a database via cellular networks when the patient removes the strip from the device. The iGlucose monitor does not require any recording on the part of the patient. The iGlucose data is managed through a HIPAA-compliant Amazon Web Services (AWS) database maintained by Smartmeter. The data is available to the provider to monitor the patient's blood glucose levels accurately and in a timely manner, allowing for treatment to be adjusted. The data is available for the physician during every patient contact for review and discussion.

Patients will be provided with the iGlucose monitor at the baseline data collection. A trained bilingual research assistant will review the iGlucose guide with the participant, provide training on the use of the monitor, taking a blood glucose reading with the monitor, and the patient will use the iGlucose monitor once in front of the research assistant. The patient will receive a packet of information in their language of choice (English and/or Marshallese). The packet will include information on how to use the monitor (including the iGlucose Guide) and contact information if there are any problems with the monitor during the study. The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose. The patient will return the equipment at the completion of the study.

The participant will provide their physician's information as part of the study, so that the investigators may provide access to the iGlucose blood glucose readings through the electronic guidebook and contact the physician post-intervention to complete a survey.
In accordance with disclosed embodiments, there are provided systems, methods, and apparatuses for integrating a body joint rehabilitation regimen with a wearable movement capture device operable in conjunction with a cloud based computing environment. For instance, a wearable apparatus for monitoring activity of a body joint such as knee or elbow for monitoring rehabilitation and recovery after surgical procedures and after injury to the joint is disclosed. Such a wearable apparatus includes a wearable harness in which a first portion of the wearable harness includes an proximal strap to be positioned proximal to the body joint and in which a second portion of the wearable harness includes a distal strap to be positioned distal to the body joint, in which the wearable harness is positionable upon a patient's body at the body joint without occluding a surgical site of the patient. Such a wearable harness further includes a connecting section having a first end connected with the proximal strap and a second end connected with the distal strap and a first buckle housing (smart buckle) secured to the proximal strap of the wearable harness and a second buckle housing secured to the distal strap of the wearable harness, in which the proximal and distal straps maintain the first and the second buckles in a consistent position relative to the axis of an underlying bone such as a thigh bone, calf bone, femur, or tibia of a patient. The wearable harness further includes integrated circuitry including at least a magnetometer and accelerometer within the first buckle and an accelerometer within the second buckle. A microprocessor of the smart buckle periodically reads a switch position on the buckles, reads the magnetometer and accelerometer data and processes the data to determine (i) an angle for the sample period, and periodically classify an activity (e.g., as walking, standing, sitting, elevating, and icing, etc.). Such data is relayed to a cloud computing environment for further analysis and for access by clinicians and patients. Other related embodiments are disclosed.
Social VR (SocVR) intervention is developed to enhance the social interaction skills of children. The participants will wear a head-mounted display (HMD) for the SocVR intervention. Each session of the SocVR intervention lasts for a maximum of 20 minutes to ensure the participants focus on the intervention and prevent causing any physical effect (Yamaguchi, 1999). The intervention contains three real-life virtual scenarios, including (1) classroom and playground, (2) MTR station and compartment, and (3) street and building. One scenario will be adopted in each session. The sequences of the scenarios used in each session will be the same for all participants. During the SocVR intervention, one RA will also appear as one avatar in the scenario to guide the participants to complete a series of tasks. Each intervention session will be conducted in a classroom independently for each participant.
PROBLEM TO BE SOLVED: To obtain a medicinal agent containing a specific compound as active ingredient, and capable of curing tumors such as lung cancer and colon cancer without destructing the tissue around the lesions. SOLUTION: This medicinal agent contains a poly(hexamethylene)biguanide or its salt <=15,000 in average molecular weight. In this case, it is preferable that the poly(hexamethylene)biguanide is used in combination with a surface tension-suppessive agent (e.g. polyethylene glycol) in the weight ratio of the former to the latter of (6:1) to (24:1). This agent is esp. effective for treating colon cancer.
Diabetes mellitus type II is the consequence of insulin resistance and pancreatic beta cell failure resulting from a variety of metabolic insults, one of which is excess body adiposity/obesity. In the diabetic individual, hepatic gluconeogenesis may go uninhibited due to failure of the body's normal feedback mechanisms to appropriately incorporate glucose into cells via insulin signaling, leading to excess gluconeogenesis and hyperglycemia. The substrate for this excess glucose derives from multiple sources in the liver including dietary glycerol, adipose-derived glycerol from lipolysis, and substrates from the citric acid cycle. In the normal state, lipolysis is maintained at a steady state in equilibrium between stored dietary triglycerides and free fatty acids. However, in situations of triglyceride excess (e.g. in the obese state), lipolysis may become overactive resulting in increased free fatty acids and adipose-derived glycerol. This excess glycerol drives hepatic gluconeogenesis and is incorporated into glucose and released into the blood, leading to hyperglycemia, and ultimately diabetes and its clinical sequelae.

A popular hypothesis linking visceral fat with excess gluconeogenesis is delivery of glycerol arising from mesenteric triglyceride turnover directly into the portal circulation and to the liver. Glycerol is a primary substrate for gluconeogenesis in the liver. Under normal conditions, hepatic gluconeogenesis begins from glycerol ingested in the diet which is converted to glycerol-3-phosphate and subsequently dihydroxyacetone phosphate (DHAP) in the liver. DHAP is converted to fructose-1,6-bisphosphate which undergoes a series of reactions to become a single 6-carbon glucose molecule. Adipocytes contribute glycerol to hepatic gluconeogenesis through lipolysis of triglyceride stores. Although glycerol-gluconeogenesis has been extensively studied in animals, the traditional reliance on radioactive tracers makes translation to humans difficult for many reasons. We aim to use new techniques to explore the mechanisms behind altered glucose metabolism related to excess visceral adiposity in obese adults by quantifying the relative contributions of varying substrates to liver-derived glucose. One such method uses 13C3 labeled glycerol to trace the incorporation of glycerol from dietary sources to hepatic gluconeogenesis. This technology utilizes nuclear magnetic resonance (NMR) spectroscopy, a technique that does not require ionizing radiation and has been extensively validated, to analyze the NMR spectra of plasma glucose and quantify the "percent enrichment" of the circulating glucose molecules with labeled glycerol. In turn, differences in enrichment reflect variability in hepatic glucose metabolism as it relates to the contribution of glycerol from visceral adipose tissue to gluconeogenesis.

The rationale of this project is to utilize existing technology to investigate the impact of excess visceral adiposity on glycerol metabolism in hepatic gluconeogenesis in obese adults without diabetes and to explore the effects of treatment with EMPA on visceral adiposity related glucose homeostasis.
Provided are systems and methods for aggregating, managing, and/or analyzing data, such as medical data, via a Medical Informatics Compute Cluster (MICC). In certain aspects, the methods include obtaining signal data for a subject from one or more body sensors; storing data associated with the subject; associating respective ones of the signal data with respective ones of the data associated with the subject; and storing at least a portion of the signal data or associations between the signal data and the data associated with the subject. Further, in certain aspects the methods include associating patterns within the signal data with patterns associated with the subject. The methods may facilitate creating a retrospective analysis of an event (e.g., an adverse event such as a heart attack, seizure, or hypoglycemic event), detecting the occurrence of an event (e.g., a hypoglycemic event), and/or predicting the future occurrence of an event (e.g., a hypoglycemic event). Systems for use in practicing methods of the invention are also provided. The systems and methods have utility in a variety of clinical and non-clinical applications.
We investigated optic nerve head factors associated with initial parafoveal scotoma (IPFS) in primary open-angle glaucoma. Eighty (80) patients with an IPFS and 84 patients with an initial nasal step (INS) were compared. Central retinal vascular trunk (CRVT) deviation from the Bruch's membrane opening (BMO) center was measured as a surrogate of lamina cribrosa (LC)/BMO offset, and its obliqueness was defined as the absolute value of angular deviation from the fovea-BMO axis. Proximity of retinal nerve fiber layer defect (RNFLD) was defined as the angular deviation of the inner RNFLD margin from the fovea-BMO axis. Microvasculature dropout (MvD) was defined as a focal sectoral capillary dropout with no visible microvascular network identified in the choroidal layer. Factors associated with IPFS, as compared with INS, were assessed using logistic regression analyses and conditional inference tree analysis. The IPFS group had more oblique CRVT offset (P < 0.001), RNFLD closer to the fovea (P < 0.001), more MvD (P < 0.001), and more LC defects (P < 0.001) compared to the INS group. In logistic regression analyses, obliqueness of CRVT offset (P = 0.002), RNFLD proximity (P < 0.001), and MvD (P = 0.001) were significant factors influencing the presence of IPFS. Conditional inference tree analysis showed that RNFLD closer to the fovea (P < 0.001) in the upper level, more oblique CRVT offset (P = 0.013) and presence of MvD (P = 0.001) in the lower level were associated with the probability of having IPFS. IPFS was associated with closer RNFLD location to the fovea when assessed from the BMO. Oblique LC/BMO offset may not only mask RNFLD proximity to the fovea due to a deviated funduscopic disc appearance, but also potentiate IPFS via focal LC defect and MvD.
Fluoxetine tablets are indicated for the treatment of:

  * Major Depressive Disorder (MDD). The efficacy of fluoxetine in MDD was established in one 5-week trial, three 6-week trials, and one maintenance study in adults. The efficacy of fluoxetine was also established in two 8- to 9-week trials in pediatric patients 8 to 18 years of age [see Clinical Studies (14.1)].
  * Obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The efficacy of fluoxetine in OCD was demonstrated in two 13-week trials in adults and one 13-week trial in pediatric patients 7 to 17 years of age [see Clinical Studies (14.2)].
  * Binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa. The efficacy of fluoxetine in Bulimia Nervosa was demonstrated in two 8-week trials and one 16-week trial in adults [see Clinical Studies (14.3)].
  * Panic Disorder, with or without agoraphobia. The efficacy of fluoxetine in Panic Disorder was demonstrated in two 12-week trials in adults [see Clinical Studies (14.4)].
Delayed graft function (DGF) is an early posttransplant complication predictive of adverse outcomes. This "acute kidney injury of transplantation" is often defined as allograft dysfunction requiring renal replacement within 7 d posttransplantation. DGF is an important area of study because it is emerging with efforts to expand the donor pool and address the supply-demand gap in kidney transplantation. DGF is often caused by severe kidney injury mechanisms because of multiple donors, recipients, and immunologic factors. The role of kidney biopsy, particularly in prolonged DGF, is an ongoing area of research and inquiry for clinicians and researchers alike to better define, manage, and predict outcomes of this early posttransplant event. This review aims to provide an in-depth, comprehensive summary of the literature to date on the histopathology of DGF and the role of kidney transplant biopsies in prolonged DGF.
Stroke patients often suffer from persistent physical, psychological, and motor dysfunction, which severely affect their independence in daily life. Therefore, restoration of independent ambulatory ability is one of the most important goals in stroke rehabilitation. To achieve such a goal, ambulation aids are important and necessary devices to assist their ambulatory ability or ambulation training. Whereas the use of ambulation assistive devices promotes early mobility and facilitates early restoration of function for these patients, improper or prolonged use of these devices may inevitably cause negative training effects, such as patients may become over-dependent upon the assistance offered by these devices. The formation of such dependence would hinder the progress of stroke patients to achieve the ultimate goal of independent walking without any assistive devices. To assess the influences of using ambulation assistive devices, it is therefore imperative that clinicians closely and subjectively evaluate the gait pattern and force production pattern of patients when they walk with ambulation aids. In addition, ambulation assistive devices equipped with device pressure feedback function can be used not only to assist in ambulating but also to monitor patient's level of dependence on devices. The device pressure feedback information can be used to train patients to gradually reduce their dependence on devices. To date, due to the limitations of conventional laboratory methods of gait analysis, the "multi-footed" gait patterns presented by stroke patients, when they are walking with ambulation aids, have not yet been studied with biomechanical analysis. Moreover, whether the use of ambulation assistive devices equipped with feedback function can effectively improve stroke patients' gait patterns or their ability to achieve independent walking remains unknown. Answers to both questions would provide important knowledge for clinicians to base upon in evaluating weight bearing symmetry between the two lower extremities in stroke patients and the training effects of using ambulation aids for these patients.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways characterized by impaired lung function induced by cigarette smoke (CS). Reduced DACH1 (dachshund homolog 1) expression has a detrimental role in numerous disorders, but its role in COPD remains understudied. This study aimed to elucidate the role and underlying mechanism of DACH1 in airway inflammation in COPD by measuring DACH1 expression in lung tissues of patients with COPD. Airway epithelium-specific DACH1-knockdown mice and adenoassociated virus-transfected DACH1-overexpressing mice were used to investigate the role of DACH1 and the potential for therapeutic targeting in experimental COPD caused by CS. Furthermore, we discovered a potential mechanism of DACH1 in inflammation induced by CS extract stimulation in vitro. Compared with nonsmokers and smokers without COPD, patients with COPD had reduced DACH1 expression, especially in the airway epithelium. Airway epithelium-specific DACH1 knockdown aggravated airway inflammation and lung function decline caused by CS in mice, whereas DACH1 overexpression protected mice from airway inflammation and lung function decline. DACH1 knockdown and overexpression promoted and inhibited IL-6 and IL-8 secretion, respectively, in 16HBE human bronchial epidermal cells after CS extract stimulation. NRF2 (nuclear factor erythroid 2-related factor 2) was discovered to be a novel downstream target of DACH1, which binds directly to its promoter. By activating NRF2 signaling, DACH1 induction reduced inflammation. DACH1 levels are lower in smokers and nonsmoking patients with COPD than in nonsmokers. DACH1 has protective effects against inflammation induced by CS by activating the NRF2 signaling pathway. Targeting DACH1 is a potentially viable therapeutic approach for COPD treatment.
The present invention discloses a plaster for relieving asthma and stopping cough, and a preparation method thereof. The plaster for relieving asthma and stopping cough is primarily prepared from the following raw materials: 1.8 to 2.2 of ephedra, 1.8 to 2.2 of white mustard seed, 0.4 to 0.6 of gansui root, 0.9 to 1.1 of pink reineckea herb, 1.4 to 1.6 of perilla fruit, 0.9 to 1.1 of manchurian wildginger, 0.4 to 0.5 of pungent oleaster fruit and 0.9 to 1.1 of japanese ardisia herb. The traditional Chinese medicinal plaster for relieving asthma and stopping cough which is prepared according to the substrate formula and the preparation method of the plaster of the present invention has the advantages of no harmful effect on the stability of sovereign drug and no side effect; the stickiness and the elasticity of the plaster are moderate, no plaster exists on skin and the paste body does not deform. The plaster can be used repeatedly with long drug efficiency and strong slow release function, and can be made into traditional Chinese medicine plaster containing different traditional Chinese medicine components; the clinical treatment indicates that the plaster for relieving asthma and stopping cough has the efficiencies of diffusing the lung, depressing qi, eliminating phlegm and relieving asthma, and can be used for treating asthma, cough, excessive phlegm, etc. with preferable therapeutic effect. During verification, no toxic or side effect, or adverse reaction occurs, and the use is convenient and safe.
PURPOSE:To obtain an easily absorbable anti-inflammatory agent causing reduced gastrointestinal injury, by agitating a non-steroidal anti-inflammatory agent and natural albumin in a specific aqueous medium at a high speed and distilling out the aqueous solvent. CONSTITUTION:The titled agent composed of a composition comprising (A) a non-steroidal anti-inflammatory agent (e.g. indomethacin, piroxicam and acetylsalicylic acid) and (B) a natural albumin (preferably ovalbumin) can be produced either by contacting the component A with the component B in an aqueous solvent under agitation at a high speed and distilling out the aqueous solvent or by dissolving the component A in a fatty oil (e.g. olive oil) and/or a fatty acid (e.g. 8-30C straight-chain fatty acid), adding the solution to an aqueous suspension of natural albumin, agitating the mixture at a high speed and distilling out the aqueous solvent. The ratio of the component A to B is 5-100:100 and the agitation is carried out preferably at room temperature at a rotational speed of 5,000-30,000rpm for 1-30hr.